Amal Therapeutics
Latest round
- Series B
Last raised
- Nov 2018
Total raised
- $37M
Investors
- 6
About Amal Therapeutics
Founded in 2012 and headquartered in Geneva, Switzerland, Amal Therapeutics SA specializes in the development of therapeutic vaccines. The company has undergone significant strategic developments, including a Trade Sale in July 2019, when Boehringer Ingelheim International GmbH acquired it for up to EUR 325 million.Amal Therapeutics specializes in developing innovative therapeutic vaccines aimed at enhancing cancer treatment through its proprietary immunization platform, KISIMA®. This platform is designed to stimulate the immune system by delivering multiple antigens within a single vaccine, thereby providing a comprehensive approach to cancer therapy. The company's lead product, ATP128, is a therapeutic vaccine specifically targeting metastatic colorectal cancers, a significant health challenge worldwide. Amal Therapeutics serves oncology-focused healthcare providers, research institutions, and pharmaceutical partners primarily in Europe and the United States, focusing on markets where there is a critical need for effective cancer therapies.Amal Therapeutics generates revenue through strategic partnerships and collaborations within the pharmaceutical and biotechnology sectors. The company engages in B2B transactions, primarily collaborating with larger pharmaceutical firms to co-develop and distribute its therapeutic vaccines. Revenue structures may include milestone payments and royalties based on the success of product development and commercialization efforts. The flagship product, ATP128, plays a crucial role in these transactions, as it represents a significant advancement in cancer therapy and is likely central to partnership agreements.Going forward, Amal Therapeutics is focused on expanding its product portfolio with new therapeutic vaccines, leveraging its KISIMA® platform. The company is also targeting expansion into new markets, particularly in North America and Asia, by 2022. The recent Trade Sale finalized on July 15, 2019, with Boehringer Ingelheim International GmbH, provides significant financial backing of up to EUR 325 million to support ongoing research and development of its products and facilitate market entry initiatives.
Who invested in Amal Therapeutics
6 investors across 4 rounds
See all investors in Amal Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Amal Therapeutics
Who invested in Amal Therapeutics?
Amal Therapeutics has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Amal Therapeutics raised?
Amal Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Amal Therapeutics last raise money?
Amal Therapeutics's most recent round on record is a Series B, in Nov 2018.
What does Amal Therapeutics do?
Founded in 2012 and headquartered in Geneva, Switzerland, Amal Therapeutics SA specializes in the development of therapeutic vaccines.
Where is Amal Therapeutics headquartered?
Amal Therapeutics is headquartered in Geneva, Switzerland.
Which VCs invest in companies like Amal Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Amal Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Amal Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.